Centessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Significant Growth in Short Interest

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 5,460,000 shares, a growth of 31.6% from the February 13th total of 4,150,000 shares. Approximately 6.9% of the shares of the company are short sold. Based on an average daily trading volume, of 772,500 shares, the short-interest ratio is presently 7.1 days.

Insider Transactions at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $17.44, for a total value of $959,200.00. Following the transaction, the chief executive officer now owns 520,661 shares in the company, valued at $9,080,327.84. The trade was a 9.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the completion of the sale, the general counsel now directly owns 118,265 shares in the company, valued at $1,808,271.85. This trade represents a 4.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 275,605 shares of company stock worth $4,643,570 in the last 90 days. Insiders own 11.59% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of CNTA. GF Fund Management CO. LTD. bought a new stake in Centessa Pharmaceuticals during the 4th quarter valued at $31,000. GAMMA Investing LLC raised its holdings in Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after acquiring an additional 865 shares during the period. Barclays PLC raised its holdings in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after acquiring an additional 4,952 shares during the period. BNP Paribas Financial Markets bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth $162,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth $171,000. Institutional investors own 82.01% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on CNTA. Morgan Stanley reaffirmed an “overweight” rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Finally, TD Cowen began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $26.00.

Centessa Pharmaceuticals Trading Up 1.6 %

Shares of CNTA stock opened at $17.14 on Monday. The company’s fifty day simple moving average is $16.45 and its two-hundred day simple moving average is $16.31. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals has a 1 year low of $7.75 and a 1 year high of $19.09. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of -11.20 and a beta of 1.54.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.